Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today reported financial results for the quarter ended March 31, 2020 and provided an update on corporate progress. "Exicure has continued to execute on its core clinical and preclinical objectives for 2020… Read More..

- Company continues to advance Phase 2b CONTROL study focused on moderate to severe subtypes of congenital ichthyosis - Foundation for Ichthyosis and Related Skin Types (FIRST) to host webinar on new ichthyosis research WOODCLIFF LAKE, N.J., May 12, 2020 /PRNewswire/ -- Timber Pharmaceuticals LLC ("Timber"), a privately held biopharmaceutical… Read More..

ANN ARBOR, Mich., May 11, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (“Zomedica” or “Company”), a veterinary diagnostic company, today reported consolidated financial results for the first quarter ended March 31, 2020. Amounts, unless specified otherwise, are expressed in U.S. dollars and presented under accounting principles generally accepted… Read More..